Pharmaceuticals (Basel, Switzerland)
June 29, 2026
Dilorom Begmatova, Liudmila Vinnikova, Natalya Zemliana et al.
Background: Adolescence is a sensitive period for brain maturation during which exposure to Δ9-tetrahydrocannabinol (THC) can induce long-lasting neurobehavioral alterations. Yet, preclinical and clinical studies report inconsistent long-term outcomes of adolescent THC exposure, ranging from clear impairments to apparently normalizing effects. We hypothesize that these discrepancies reflect...
Substance Use & Misuse
February 1, 2026
Kai-Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt et al.
Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...
Science academique
2026
Kenneth Blum, Kai-Uwe Lewandrowski, Morgan P Lorio et al.
The aim of this perspective article is to evaluate the potential of Psychedelics in the management of Alcohol Use Disorder (AUD) vis-a-vis pre-existing therapeutic modalities and to elucidate practical directions for policy in AUD Addiction medicine, supported by scientific evidence, while prioritizing safety and accessibility. We performed a narrative synthesis of past and current literature...
Pharmaceuticals (Basel, Switzerland)
August 29, 2025
Gustavo N Silva, Virna G A Brandão, Kenneth Blum et al.
7 citations
Ketamine, a widely used anesthetic with emerging evidence suggesting neuroprotective and anti-inflammatory properties across various neurological disorders, is recognized for its NMDA receptor antagonism. It has been postulated to play a role in neuroprotection, due to its anti-inflammatory properties, and decrease microglial activation, as well as cytokines TNF and IL-6. Despite its...
Frontiers in Public Health
January 25, 2024
Yu Kyung Lee, Mark S. Gold, Kenneth Blum et al.
45 citations
Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19...
Current Psychopharmacology
February 15, 2021
Kenneth Blum, Thomas Mclaughlin, Edward J Modestino et al.
9 citations
During Lucid Dreams, the dreamer is aware, experiences the dream as if fully awake, and may control the dream content. The dreamer can start, stop, and restart dreaming, depending on the nature and pleasantness of the dream. For patients with Reward Deficiency Syndrome (RDS) behaviors, like Attention Deficit Hyperactivity Disorder (ADHD), Tourette's- Syndrome, and Posttraumatic Stress Disorder...
Journal of reward deficiency syndrome and addiction science
2016
Thomas Mclaughlin, Marcelo Febo, Rajendra D Badgaiyan et al.
Recent reports by our laboratory have indicated that lucid dreams may be linked to psychiatric conditions, including Attention Deficit Hyperactivity Disorder (ADHD) and other Reward Deficiency Syndrome-related diagnoses. In the latter case, it has been our observation that such lucid dreams can be unpleasant and frequently terrifying. We present four cases of a dramatic and persistent...
Clinical Toxicology
1977
Kenneth Blum, San Ford L. Futterman, Paul Pascarosa
34 citations
The authors examine folk psychiatry among Native American Church members from an enthnopharmacologic viewpoint. Alcohol and opiate abuse among Indian and non-Indian are presented in case histories proving to be asymptomatic under Indian guidance and through participation in the peyote ritual. The biochemical alkaloids common in the peyote cactus, rather than just the psychoactive substances...